ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Wednesday, November 15, 2023

11:00AM-12:30PM: Abstract Number: 2585

Cytokine and Chemokine Elevations in ACPA+ Individuals Suggest Possible Viral, Mucosal and/or Innate Responses Are Related to the Transition to Future Clinical RA

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2582

Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2597

Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

11:00AM-12:30PM: Abstract Number: 2593

FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

11:00AM-12:30PM: Abstract Number: 2584

Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2596

Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

11:00AM-12:30PM: Abstract Number: 2601

Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

11:00AM-12:30PM: Abstract Number: 2603

Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

11:00AM-12:30PM: Abstract Number: 2587

Measuring Frailty in SLE: Agreement Among Methods

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes IV: Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2604

Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

11:00AM-12:30PM: Abstract Number: 2581

Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies

Abstracts: RA – Diagnosis, Manifestations, and Outcomes IV: Pre-RA & RA Diagnosis

11:00AM-12:30PM: Abstract Number: 2589

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes IV: Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2602

Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

11:00AM-12:30PM: Abstract Number: 2599

Study of the Role of interleukin-17 in Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders III: Innovation

11:00AM-12:30PM: Abstract Number: 2594

Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Abstracts: Systemic Sclerosis & Related Disorders III: Clinical Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].